ArticleNPJ precision oncology2025
Predicting tumor micronecrosis in hepatocellular carcinoma using pretreatment contrast-enhanced CT radiomics model: a multi-center study.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable machine learning for Parkinson's disease diagnosis, staging, and biological mechanism exploration: a multicenter analysis.BioData mining · 2026Article
- A Noninvasive Predictive Model of Portal Hypertension in Patients with HCC Based on Clinical Features and Intra- and Peritumoral Pre-Fusion Radiomic Features.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
Tumor micronecrosis is a validated malignancy biomarker with poor prognosis in hepatocellular carcinoma (HCC), but currently lacks reliable preoperative detection methods. We developed a radiomics model for predicting tumor micronecrosis using preoperative contrast-enhanced computed tomography (CECT). The study included 1017 patients with histopathologically confirmed HCC across three centers, allocated to development, internal test, external test, and application sets. Radiomics features were extracted from tumor regions, with model training via a stratified 5-fold cross-validation framework. The model yield area under the curve values of 0.80 and 0.75 in the internal and external test sets, respectively. Survival curves for histologic and radiomics-predicted micronecrosis groups demonstrated close alignment. For patients treated with tyrosine kinase inhibitor and anti-PD-(L)1 immunotherapy, radiomics-predicted micronecrosis(-) and micronecrosis(+) groups showed comparable survival (P = 0.312). Mass cytometry demonstrated significant correlations between micronecrosis-associated radiomics features and peripheral CD24
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.